These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 29665944)

  • 41. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.
    Wang Z; Guo Y; Han W
    Protein Cell; 2017 Dec; 8(12):896-925. PubMed ID: 28466386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.
    Lin WY; Wang HH; Chen YW; Lin CF; Fan HC; Lee YY
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
    Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
    Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
    Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
    Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
    Date V; Nair S
    Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
    Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CAR-T cells beyond CD19, UnCAR-Ted territory.
    Leick MB; Maus MV
    Am J Hematol; 2019 May; 94(S1):S34-S41. PubMed ID: 30632631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
    Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
    Bouziana S; Bouzianas D
    Crit Rev Oncol Hematol; 2021 Jan; 157():103096. PubMed ID: 33181441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status of chimeric antigen receptor therapy for haematological malignancies.
    Maude S; Barrett DM
    Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CAR-T Cell Therapies From the Transfusion Medicine Perspective.
    Fesnak A; Lin C; Siegel DL; Maus MV
    Transfus Med Rev; 2016 Jul; 30(3):139-45. PubMed ID: 27067907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA Investigating CAR-Related T-cell Malignancies.
    Cancer Discov; 2024 Jan; 14(1):9-10. PubMed ID: 38032843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
    Yoon DH; Osborn MJ; Tolar J; Kim CJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.